JP2015514718A - スクシンイミド活性化されたニトロキシル化合物およびタンパク質のニトロキシル化のためのその使用のための方法 - Google Patents

スクシンイミド活性化されたニトロキシル化合物およびタンパク質のニトロキシル化のためのその使用のための方法 Download PDF

Info

Publication number
JP2015514718A
JP2015514718A JP2015504603A JP2015504603A JP2015514718A JP 2015514718 A JP2015514718 A JP 2015514718A JP 2015504603 A JP2015504603 A JP 2015504603A JP 2015504603 A JP2015504603 A JP 2015504603A JP 2015514718 A JP2015514718 A JP 2015514718A
Authority
JP
Japan
Prior art keywords
protein
lysine
nitroxylated
hemoglobin
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015504603A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015514718A5 (enExample
Inventor
キム・ディ・バンデグリフ
アショク・マラバリ
ネル・ムクルトチャン
Original Assignee
サンガート， インコーポレイテッド
サンガート， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サンガート， インコーポレイテッド, サンガート， インコーポレイテッド filed Critical サンガート， インコーポレイテッド
Publication of JP2015514718A publication Critical patent/JP2015514718A/ja
Publication of JP2015514718A5 publication Critical patent/JP2015514718A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
JP2015504603A 2012-04-03 2013-03-15 スクシンイミド活性化されたニトロキシル化合物およびタンパク質のニトロキシル化のためのその使用のための方法 Pending JP2015514718A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261619783P 2012-04-03 2012-04-03
US201261619768P 2012-04-03 2012-04-03
US61/619,768 2012-04-03
US61/619,783 2012-04-03
PCT/US2013/032704 WO2013151776A1 (en) 2012-04-03 2013-03-15 Succinimide-activated nitroxyl compounds and methods for the use thereof for nitroxylation of proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018089859A Division JP6686067B2 (ja) 2012-04-03 2018-05-08 スクシンイミド活性化されたニトロキシル化合物およびタンパク質のニトロキシル化のためのその使用のための方法

Publications (2)

Publication Number Publication Date
JP2015514718A true JP2015514718A (ja) 2015-05-21
JP2015514718A5 JP2015514718A5 (enExample) 2016-04-28

Family

ID=49300942

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015504603A Pending JP2015514718A (ja) 2012-04-03 2013-03-15 スクシンイミド活性化されたニトロキシル化合物およびタンパク質のニトロキシル化のためのその使用のための方法
JP2018089859A Expired - Fee Related JP6686067B2 (ja) 2012-04-03 2018-05-08 スクシンイミド活性化されたニトロキシル化合物およびタンパク質のニトロキシル化のためのその使用のための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018089859A Expired - Fee Related JP6686067B2 (ja) 2012-04-03 2018-05-08 スクシンイミド活性化されたニトロキシル化合物およびタンパク質のニトロキシル化のためのその使用のための方法

Country Status (9)

Country Link
US (3) US20150094267A1 (enExample)
EP (1) EP2834329B1 (enExample)
JP (2) JP2015514718A (enExample)
KR (1) KR102076874B1 (enExample)
CN (1) CN104411807B (enExample)
AU (2) AU2013243875B2 (enExample)
CA (1) CA2908238C (enExample)
MX (1) MX358784B (enExample)
WO (1) WO2013151776A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015514718A (ja) * 2012-04-03 2015-05-21 サンガート， インコーポレイテッド スクシンイミド活性化されたニトロキシル化合物およびタンパク質のニトロキシル化のためのその使用のための方法
JP6657070B2 (ja) * 2013-03-15 2020-03-04 ウィリアム・シンドラーＷｉｌｌｉａｍ Ｓｃｈｉｎｄｌｅｒ ポリアルキレンオキシド吉草酸ヘモグロビン接合体
EP2894476A1 (en) * 2014-01-14 2015-07-15 Universität Konstanz Genetically Encoded Spin Label
EP3380107B1 (en) * 2015-11-24 2023-03-15 Antiradical Therapeutics LLC Compositions and methods of use of nano anti-radical therapeutics to inhibit cancer
CN105777893B (zh) * 2016-03-24 2019-10-25 杭州亚慧生物科技有限公司 一种高强度血清白蛋白骨修复材料及其制备方法
CA3070172A1 (en) 2017-07-18 2019-01-24 VirTech Bio, Inc. Blood substitutes comprising hemoglobin and methods of making
CN114279777A (zh) * 2020-09-28 2022-04-05 深圳市瑞图生物技术有限公司 一种含有脒基类化合物的溶血剂及其血液分析试剂盒
CU24689B1 (es) * 2020-10-05 2023-12-07 Ct Inmunologia Molecular CONJUGADOS COVALENTES DEL DOMINIO DE UNIÓN AL RECEPTOR DEL VIRUS SARS-CoV-2 Y UNA PROTEÍNA PORTADORA Y PROCEDIMIENTO DE OBTENCIÓN
CN118684612B (zh) * 2024-08-26 2025-11-18 浙江瑞奥生物科技有限公司 一种马来聚乙二醇药物偶联剂的合成方法
CN120682395B (zh) * 2025-08-20 2025-11-07 复星安特金(成都)生物制药有限公司 一种活化细菌荚膜多糖的方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05504133A (ja) * 1989-11-22 1993-07-01 エンゾン，インコーポレーテッド 効果的で、安定した、非免疫原性の赤血球代替物としての化学的修飾ヘモグロビン
JPH08502023A (ja) * 1992-10-13 1996-03-05 エンゾン，インコーポレーテッド ポリアルキレンオキシド複合化ヘモグロビン溶液の分画
JPH09501681A (ja) * 1993-08-16 1997-02-18 シャー、ジェン−チャン ニトロキシドを用いる酸素毒性の防止用組成物と防止法
JP2006502250A (ja) * 2002-07-24 2006-01-19 エフ．ホフマン−ラ　ロシュ　アーゲー ポリアルキレングリコール酸添加剤
JP2008074876A (ja) * 1995-03-31 2008-04-03 Synzyme Technologies Inc ニトロキシドを生体適合性高分子と併用する組成物および方法
WO2011106396A1 (en) * 2010-02-25 2011-09-01 Sangart, Inc. Methods for preparing peg-hemoglobin conjugates using reduced reactant ratios
CN102249987A (zh) * 2011-05-06 2011-11-23 兰州大学 一种考布他汀类化合物及其制备方法和用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4240797A (en) 1977-10-18 1980-12-23 The Governing Council Of The University Of Toronto Assay for reserve bilirubin binding capacity
US4529719A (en) 1983-05-04 1985-07-16 Tye Ross W Modified crosslinked stroma-free tetrameric hemoglobin
US5004809A (en) * 1986-02-04 1991-04-02 University Of Cincinnati Nitroxide labeled nucleotides and nitroxide labeled hybridization probes
CA1312009C (en) 1986-11-10 1992-12-29 Carl W. Rausch Extra pure semi-synthetic blood substitute
GB8710598D0 (en) 1987-05-05 1987-06-10 Star Medical Diagnostics Ltd Hemoglobin based blood substitute
US5650388A (en) 1989-11-22 1997-07-22 Enzon, Inc. Fractionated polyalkylene oxide-conjugated hemoglobin solutions
US5250665A (en) 1991-05-31 1993-10-05 The University Of Toronto Innovations Foundation Specifically β-β cross-linked hemoglobins and method of preparation
US5840701A (en) 1993-08-16 1998-11-24 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US6458758B1 (en) 1993-08-16 2002-10-01 Synzyme Technologies, Inc. Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5585484A (en) 1995-04-19 1996-12-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Hemoglobin crosslinkers
US6627738B2 (en) 1995-09-15 2003-09-30 Duke University No-modified hemoglobins and uses therefor
DE10031740A1 (de) 2000-06-29 2002-02-14 Sanguibio Tech Ag Künstliche Sauerstoffträger aus vernetztem modifizierten Human- oder Schweinehämoglobin mit verbesserten Eigenschaften, Verfahren zu ihrer technisch einfachen Herstellung aus gereinigtem Material in hohen Ausbeuten, sowie deren Verwendung
US20030153491A1 (en) 2002-01-11 2003-08-14 Winslow Robert M. Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
DE10393955T5 (de) * 2002-12-23 2005-12-29 L'oreal Zusammensetzung zum Färben von Keratinfasern, die mindestens eine freiradikalische Verbindung vom Nitroxyl-Typ und mindestens einen primären oder sekundären Alkohol enthält
CA2511494A1 (en) 2002-12-23 2004-07-15 Seetharama A. Acharya Non-hypertensive polyethylene glycol-modified hemoglobin as oxygen carrier
KR100512483B1 (ko) 2003-05-07 2005-09-05 선바이오(주) 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법
WO2006014968A2 (en) 2004-07-27 2006-02-09 Teva Pharmaceutical Industries, Ltd. Propargyl nitroxydes and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders
TW200616604A (en) * 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
WO2006096774A2 (en) 2005-03-07 2006-09-14 Sangart, Inc. Composition and methods for delivering carbon monoxide (co) and nitric ozide (no) co to tissue using heme proteins as carriers
US8741832B2 (en) * 2005-06-10 2014-06-03 Albert Einstein College Of Medicine Of Yeshiva University Pegylated albumin and uses thereof
EP2184987A4 (en) * 2007-07-31 2011-09-28 Burnham Inst Medical Research BIDENTATE COMPOUNDS AS KINASEHEMMER
EP2030624A1 (en) * 2007-08-28 2009-03-04 Johannes Gutenberg Universität Antioxidant and paramagnetic heparin-nitroxide derivatives
NO2440239T3 (enExample) 2009-06-09 2018-02-10
US8273857B2 (en) 2009-09-22 2012-09-25 Jen-Chang Hsia Compositions and methods of use of neurovascular protective multifunctional polynitroxylated pegylated carboxy hemoglobins for transfusion and critical care medicine
JP2015514718A (ja) 2012-04-03 2015-05-21 サンガート， インコーポレイテッド スクシンイミド活性化されたニトロキシル化合物およびタンパク質のニトロキシル化のためのその使用のための方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05504133A (ja) * 1989-11-22 1993-07-01 エンゾン，インコーポレーテッド 効果的で、安定した、非免疫原性の赤血球代替物としての化学的修飾ヘモグロビン
JPH08502023A (ja) * 1992-10-13 1996-03-05 エンゾン，インコーポレーテッド ポリアルキレンオキシド複合化ヘモグロビン溶液の分画
JPH09501681A (ja) * 1993-08-16 1997-02-18 シャー、ジェン−チャン ニトロキシドを用いる酸素毒性の防止用組成物と防止法
JP2008074876A (ja) * 1995-03-31 2008-04-03 Synzyme Technologies Inc ニトロキシドを生体適合性高分子と併用する組成物および方法
JP2006502250A (ja) * 2002-07-24 2006-01-19 エフ．ホフマン−ラ　ロシュ　アーゲー ポリアルキレングリコール酸添加剤
WO2011106396A1 (en) * 2010-02-25 2011-09-01 Sangart, Inc. Methods for preparing peg-hemoglobin conjugates using reduced reactant ratios
CN102249987A (zh) * 2011-05-06 2011-11-23 兰州大学 一种考布他汀类化合物及其制备方法和用途

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 320(1), JPN6017002596, 1995, pages 155 - 61, ISSN: 0003487453 *
JOURNAL OF CONTROLLED RELEASE, vol. 111(1-2), JPN6017002598, 2006, pages 73 - 80, ISSN: 0003487454 *
MACROMOLECULES, vol. 44(7), JPN6017002604, 2011, pages 1747 - 1751, ISSN: 0003487456 *
SYMP. PAP. - IUPAC INT. SYMP. CHEM. NAT. PROD., 11TH, vol. 1, JPN6017002600, 1978, pages 87 - 90, ISSN: 0003487455 *

Also Published As

Publication number Publication date
EP2834329B1 (en) 2018-10-17
AU2013243875B2 (en) 2017-11-30
AU2018201285B2 (en) 2020-05-14
US20150094267A1 (en) 2015-04-02
JP2018150335A (ja) 2018-09-27
AU2018201285A1 (en) 2018-03-22
EP2834329A4 (en) 2015-12-23
MX358784B (es) 2018-09-04
CA2908238A1 (en) 2013-10-10
CA2908238C (en) 2023-01-10
KR102076874B1 (ko) 2020-02-12
CN104411807A (zh) 2015-03-11
US11359004B2 (en) 2022-06-14
AU2013243875A1 (en) 2014-11-20
HK1207659A1 (en) 2016-02-05
JP6686067B2 (ja) 2020-04-22
EP2834329A1 (en) 2015-02-11
KR20140144262A (ko) 2014-12-18
US20230026348A1 (en) 2023-01-26
US20190127445A1 (en) 2019-05-02
MX2014011944A (es) 2015-06-05
WO2013151776A1 (en) 2013-10-10
CN104411807B (zh) 2018-10-02

Similar Documents

Publication Publication Date Title
JP6686067B2 (ja) スクシンイミド活性化されたニトロキシル化合物およびタンパク質のニトロキシル化のためのその使用のための方法
JP6668515B2 (ja) ジアスピリン架橋ｐｅｇヘモグロビン
CA2906878C (en) Polyalkylene oxide valerate hemoglobin conjugates
HK1207659B (zh) 琥珀酰亚胺活化型硝酰化合物及其用於蛋白质硝酰化的使用方法
HK1219053B (zh) 聚环氧烷戊酸酯血红蛋白缀合物

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150715

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160309

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160309

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170728

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180109

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20180329